Key result
Bromocriptine is discussed as a treatment for peripartum cardiomyopathy, a condition with an incidence ranging from ~1:3000 to 1:100 pregnancies and mortality rates varying from <5% up to 50%.
Why the study?
Does bromocriptine improve outcomes in women with peripartum cardiomyopathy?
Does bromocriptine improve outcomes in women with peripartum cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Bromocriptine is a promising treatment option for PPCM in addition to therapy with the medications usually used for heart failure. In a large, global PPCM registry with 552 PPCM patients, we confirmed the efficacy of bromocriptine and showed that it significantly improves maternal cardiac health.”
“The term multicentre randomized in its title is misleading. There was no placebo group in the study for comparison with bromocriptine group. Both the groups received bromocriptine rather. The comparison with IPAC study is having a profound racial bias.”
“These data not only confirm the efficacy but also the safety of our therapeutic approach.”
This editorial introduces a multicentre randomized study evaluating bromocriptine for the treatment of peripartum cardiomyopathy, highlighting the variable global epidemiology and outcomes of the disease.
This editorial refers to ‘Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study’†, by D. Hilfiker-Kleiner et al., on page 2671. Peripartum cardiomyopathy (PPCM), according to the actual definition proposed by the Study Group on PPCM of the Heart Failure Association of the European Society of Cardiology (ESC), is an idiopathic cardiomyopathy frequently presenting with left ventricular (LV) systolic dysfunction (LV ejection fraction <45%) towards the end of pregnancy or in the months following delivery in the absence of other causes.1 The most common clinical presentation consists of acute heart failure (AHF) occurring in the first weeks after delivery. The worldwide burden of PPCM is estimated based on single-centre case series from Haiti, South Africa, and the USA showing incidences ranging from ∼1:3000 to 1:100 pregnancies. Women of African origin display a significantly higher risk of developing PPCM.2 The clinical outcome of women with PPCM seems to vary across the world, probably because of differences in ethnic and social factors and access to AHF treatment, but also due to heterogeneity in the inclusion criteria in the studies. Accordingly, reported mortality rates may vary from <5% up to 50%. Moreover, despite the fact that several publications reported rapid recovery of LV function (within 6 months after diagnosis) in the majority of patients,3 other studies reported delayed LV recovery in a significant proportion of patients.4 Notably, Afro-American women showed lower rates of recovery and worse prognosis compared with Caucasians.4 New insights into the epidemiology and outcome of PPCM from the EURObservational Research Programme of the ESC may, however, suggest comparable outcome between European and non-European regions.5
No takes yet. Share an insight, caveat, or question.
Arrigo et al. (2017) conducted an editorial in Peripartum cardiomyopathy. Bromocriptine was evaluated. Bromocriptine is discussed as a treatment for peripartum cardiomyopathy, a condition with an incidence ranging from ~1:3000 to 1:100 pregnancies and mortality rates varying from <5% up to 50%.
Synapse has enriched 10 related papers. Consider them for comparative context: